Welcome, Guest. Please login or register.
October 17, 2019, 04:12:37 am

Login with username, password and session length


Members
Stats
  • Total Posts: 748213
  • Total Topics: 62738
  • Online Today: 312
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 am)
Users Online
Users: 3
Guests: 261
Total: 264

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: People with multidrug resistant HIV reach UD with Trogarzo antibody + ART  (Read 590 times)

0 Members and 1 Guest are viewing this topic.

Online Jim Allen

  • Administrator
  • Member
  • Posts: 13,247
  • Twitter @JimAllenDublin
    • HIV Lessons
Study was aimed at people with multidrug-resistant HIV who during the study were given the antibody treatment Trogarzo (ibalizumab) + ART and they reached viral suppression for a year.

Cool.

In Full: https://www.poz.com/article/trogarzo-can-keep-viral-load-suppressed-least-year

In Short:
Quote
The participants had HIV that was resistant to at least one medication in three or more classes of antiretrovirals (ARVs). On day seven of the study they received a 2,000 milligram infusion of Trogarzo. On day 14, they were started on a standard ARV regimen optimized based on drug resistance testing. Starting on day 21, they received an 800 mg infusion of Trogarzo every 14 days.

Seventeen participants (43 percent) achieved a fully suppressed viral load 24 weeks into the study. Of the 31 participants who finished the 24-week study, 27 entered the expanded access phase. Twenty-four of them completed the additional 24 weeks of follow-up; of these, 16 (67 percent) had a fully suppressed viral load at the end of that period.

Of those still on treatment by the end of the expanded access phase, the median reduction in viral load was 2.5log10, or a 99.68 percent reduction.

All 15 of those who entered the expanded access phase with a fully suppressed viral load maintained that status 24 weeks later.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

Online Jim Allen

  • Administrator
  • Member
  • Posts: 13,247
  • Twitter @JimAllenDublin
    • HIV Lessons
Update & continued good news.

Trogarzo Again Shown Effective Against Highly Resistant HIV

Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment. https://www.poz.com/article/trogarzo-shown-effective-highly-resistant-hiv

Quote
At this year’s IDWeek, Brinda Emu, MD, of Yale University, and colleagues reported findings from a larger group of 38 people enrolled in the expanded access study, known as TMB-311. Most (87%) were men, and the median age was 53. The median CD4 count was 26, and more than half had levels below 50, indicating advanced immune suppression. Again, they were resistant to antiretrovirals from at least three classes, but their virus remained fully sensitive to at least one drug.

These participants started on Trogarzo plus an optimized background regimen from the outset and did not initially take the antibody alone, unlike those in the previous trial. Here, too, they first received a 2,000 mg infusion followed by 800 mg doses every two weeks.

In this group, 57% experienced a viral load decrease of at least 1.0 log by day 7. Among the 24 participants who completed six months of treatment, 46% had viral loads below 50. The median CD4 count rose by about 30 at week 24.

Among the 17 people who continued treatment through 48 weeks, 47% maintained an undetectable viral load. However, this figure does not include seven people who withdrew from the expanded access program and started taking commercially available Trogarzo after its approval.

In both the Phase III trial and the expanded access cohort, Trogarzo was generally safe and well tolerated. The most common adverse events were diarrhea, headache, nausea, cough, skin rash and fatigue, mostly mild or moderate. No participants reported injection site reactions.

Results from the expanded access program “demonstrate durable viral suppression in this difficult-to-treat patient population,” the researchers concluded.
HIV 101 - Everything you need to know
HIV 101
Transmission and Risks:
HIV Transmission and Risks
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

 


Terms of Membership for these forums
 

© 2019 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.